State Street SPDR S&P Pharmaceuticals ETF XPH

El SPDR S&P Pharmaceuticals ETF (el Fondo) busca replicar lo más fielmente posible el rendimiento total del índice de la industria selecta de productos farmacéuticos S&P. El índice de la industria selecta de productos farmacéuticos S&P representa la porción de la subindustria farmacéutica del índice de mercados totales S&P. El S&P TMI sigue todas las acciones comunes de los Estados Unidos listadas en la Bolsa de Nueva York, la Bolsa de Valores de América, la Asociación Nacional de Corredores de Bolsa de Cotización Automatizada (NASDAQ) y las bolsas NASDAQ Small Cap. El Fondo invierte sustancialmente todos, pero al menos el 80%, de sus activos totales en los valores que componen el índice. Además, el Fondo puede invertir en valores de renta variable que no están incluidos en el índice, efectivo y equivalentes al efectivo o instrumentos del mercado monetario, como acuerdos de recompra y fondos del mercado monetario. El índice de productos farmacéuticos es un índice de peso igual modificado. SSgA Funds Management, Inc. es el asesor de inversiones del Fondo.

Con 16 acciones de XPH (USD 1.018,27) habrías recibido USD 4,32 en dividendos en los últimos 12 meses.

• The Motley Fool 10 sept

  Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

  Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

  

• The Motley Fool 8 jul

  Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH?

  The article compares two healthcare ETFs: Invesco's IBBQ and State Street's XPH. IBBQ offers lower costs (0.19% expense ratio), broader diversification (253 holdings), and higher dividend yield (0.80%), making it better for long-term investors. XPH delivered stronger 1-year returns (63.90% vs 57.20%) with less volatility but charges higher fees (0.35%) and holds only 65 positions. Both funds have significantly underperformed the S&P 500 over five years, reflecting the challenges of biotech and pharmaceutical investing.

  

• The Motley Fool 8 jul

  BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

  The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

  

• Seeking Alpha 27 may

  Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows

  Numerous drugs under development are projected to come to market later this year and next for Gilead. Read why I rate GILD stock a Buy.

  

• Zacks Investment Research 16 may

  Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

  Sector ETF report for XPH